Literature DB >> 573767

Inhibition of thyrotropin and prolactin secretion by dopamine in man.

F Massara, F Camanni, V Vergano, L Belforte, G M Molinatti.   

Abstract

The effect of dopamine on thyrotropin (TSH) and prolactin (PRL) levels was studied in 5 normal subjects, 7 women with galactorrhea, 9 acromegalics and 4 patients with primary hypothyroidism. Dopamine infused at the rate of 280 micrograms/min produced significant decrease in plasma TSH and PRL levels in all four groups, though a lower fall in TSH was noted in acromegalics. A similar reduction in PRL was also noted after 28 micrograms/min dopamine. Phentolamine infusion (0.5 mg/min) had no effect on PRL response to dopamine. These results indicate that a dopaminergic stimulation led to an inhibition of TSH and PRL secretion. Since the high polarity of dopamine impedes its passage through the blood-brain barrier, its site of action should be outside this barrier, probably in the pituitary.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 573767     DOI: 10.1007/BF03346767

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Effect of L-dopa on plasma TSH levels in primary hypothyroidism.

Authors:  M Minozzi; M Faggiano; G Lombardi; C Carella; T Criscuolo; U Scapagnini
Journal:  Neuroendocrinology       Date:  1975       Impact factor: 4.914

2.  Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report.

Authors:  E Del Pozo; H Friesen; P Burmeister
Journal:  Schweiz Med Wochenschr       Date:  1973-06-09

3.  Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel.

Authors:  J Takahara; A Arimura; A V Schally
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

4.  Levodopa suppression of prolactin in nonpuerperal galactorrhea.

Authors:  W B Malarkey; L S Jacobs; W H Daughaday
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

5.  Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses.

Authors:  C A Birge; L S Jacobs; C T Hammer; W H Daughaday
Journal:  Endocrinology       Date:  1970-01       Impact factor: 4.736

6.  Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines.

Authors:  R M MacLeod; E H Fontham; J E Lehmeyer
Journal:  Neuroendocrinology       Date:  1970       Impact factor: 4.914

7.  L-DOPA suppression of thyrotropin-releasing hormone response in man.

Authors:  S W Spaulding; G N Burrow; R Donabedian; M van Woert
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

8.  Effects of dopamine infusion on pituitary hormone secretion in humans.

Authors:  H Leblanc; G C Lachelin; S Abu-Fadil; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

9.  Effects of biogenic amines and TRH on release of prolactin and TSH in the rat.

Authors:  H J Chen; J Meites
Journal:  Endocrinology       Date:  1975-01       Impact factor: 4.736

10.  The effect of apomorphine on basal and TRH stimulated release of thyrotrophin and prolactin in man.

Authors:  K O Nilsson; L Wide; B Hökfelt
Journal:  Acta Endocrinol (Copenh)       Date:  1975-10
View more
  3 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

2.  Nomifensine decreases the thyroid-stimulating-hormone response to thyrotropin-releasing-hormone in normal subjects.

Authors:  M Giusti; G Mazzocchi; D Mignone; W Tarditi; G Giordano
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

3.  Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients.

Authors:  E Parlati; A Travaglini; I Liberale; E Menini; S Dell'Acqua
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.